Abitate 250 Mg Powder for Injection (Abiraterone Acetate)
Price range: $1,885.47 through $5,261.25Required
| Pack Size | Price | Unit Price | Quantity | |
|---|---|---|---|---|
| 1 Injection | $1,885.47 | $1,885.47 / injection | ||
| 2 Injection | $3,613.75 | $1,806.88 / injection | ||
| 3 Injection | $5,261.25 | $1,753.75 / injection |
About Abitate 250 Mg Powder for Injection (Abiraterone Acetate)
Medicine information
- Active ingredient
- Abiraterone acetate
- Delivery time
- 10–14 business days after dispatch for the United States, United Kingdom, Canada, and Australia; other destinations vary under the store shipping framework. Delivery estimates are not guaranteed and customs or local carrier delays may extend transit.
- Indication
- Treatment of metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer, in combination with prednisone and appropriate androgen-deprivation therapy where indicated.
- Manufacturer
- RPG Life Sciences Ltd
- Packaging
- Bottle of 120 tablets
- Strength
- 250 mg
- Dosage form
- Tablet
- Route
- Oral
Medicine overview
Abitate 250 mg contains abiraterone acetate, an androgen biosynthesis inhibitor used in the treatment of certain forms of metastatic prostate cancer. Verified product listings identify Abitate 250 mg as an oral tablet manufactured by RPG Life Sciences Ltd and supplied as 120 tablets per bottle. The product name “Abitate 250 mg Powder for Injection” could not be verified as an injectable formulation; available product-specific evidence identifies Abitate 250 mg as a tablet. Abiraterone is normally used with prednisone and ongoing medical or surgical androgen deprivation.
What it is used for
Abiraterone acetate is used with prednisone to treat metastatic castration-resistant prostate cancer, meaning prostate cancer that has spread and continues to progress despite treatment that lowers testosterone. It is also indicated for metastatic high-risk castration-sensitive prostate cancer. Treatment is part of a broader hormone-based prostate cancer regimen, and patients who have not undergone surgical removal of the testes generally continue appropriate androgen-deprivation therapy.
How it works
Abiraterone acetate is converted in the body to abiraterone. It blocks CYP17, an enzyme needed to make androgens such as testosterone in the testes, adrenal glands, and prostate tumour tissue. Prostate cancer cells can depend on these hormones for growth. By substantially reducing androgen production, abiraterone helps limit the hormonal stimulation that can support prostate cancer growth. Blocking CYP17 can also increase mineralocorticoid activity, which explains important risks such as high blood pressure, low potassium, and fluid retention.
How it is taken
Abiraterone acetate tablets are taken by mouth as prescribed, together with prednisone. They must be taken on an empty stomach: no food should be eaten for at least 2 hours before taking the medicine or for at least 1 hour afterward. Swallow the tablets whole with water; do not crush or chew them. Food can substantially increase abiraterone exposure and the risk of adverse reactions. If one dose is missed, the usual prescribed dose is taken the following day; more than one missed daily dose should be discussed with the treating healthcare professional.
Important warnings
Abiraterone can cause hypertension, low blood potassium, fluid retention, and cardiovascular complications; blood pressure, potassium, and signs of fluid retention require regular monitoring. Severe and sometimes fatal liver injury has occurred, so liver function must be checked before and during treatment. Adrenal insufficiency can occur, particularly if corticosteroid treatment is interrupted or during infection or physiological stress. Use with radium Ra 223 plus prednisone/prednisolone is not recommended because increased fractures and mortality have been observed. Severe hypoglycaemia has been reported in patients with diabetes taking certain medicines, including pioglitazone or repaglinide. Strong CYP3A4 inducers and medicines with a narrow therapeutic index metabolised by CYP2D6 may require special consideration. Abiraterone should not be used in patients with baseline severe hepatic impairment. Patients should promptly report fainting, irregular heartbeat, severe weakness, marked swelling, yellow skin or eyes, dark urine, or severe nausea or vomiting.
Side effects and monitoring
Common adverse effects include fatigue, joint pain, high blood pressure, nausea, swelling of the legs or feet, low potassium, hot flushes, diarrhoea, vomiting, cough, headache, and upper respiratory infections. Important serious effects include severe liver injury, adrenal insufficiency, significant hypokalaemia, fluid retention, abnormal heart rhythms, cardiovascular complications, and severe hypoglycaemia in susceptible patients. Monitoring includes blood pressure, serum potassium and fluid retention at least monthly, together with scheduled liver-function testing. Patients with diabetes may also require closer blood-glucose monitoring.
Pregnancy
Abiraterone acetate can cause fetal harm and pregnancy loss and is not indicated for use in women. Men with female partners of reproductive potential should use effective contraception during treatment and for 3 weeks after the final dose. Women who are pregnant or may become pregnant should not handle broken, crushed, or damaged abiraterone tablets without protection such as gloves.
Breastfeeding
Abiraterone is not indicated for use in women. There are no adequate data on whether abiraterone is present in human milk or on its effects on a breastfed child or milk production.
Food and drink
Abiraterone tablets must not be taken with food. No food should be eaten for at least 2 hours before the dose and for at least 1 hour afterward. Taking abiraterone with food can substantially increase drug exposure and may increase adverse reactions. Swallow the tablets whole with water.
Storage
Store at controlled room temperature, generally 20°C to 25°C, with permitted excursions from 15°C to 30°C. Keep out of reach of children.
Frequently asked questions
Why do I have to take abiraterone on an empty stomach?
Food can substantially increase the amount of abiraterone absorbed and may increase side effects. Do not eat for at least 2 hours before taking it or for at least 1 hour afterward.
Why is prednisone prescribed with abiraterone?
Prednisone is an established part of abiraterone treatment and helps manage effects associated with the hormonal changes caused by CYP17 inhibition. Do not stop prednisone or abiraterone without instructions from your treating healthcare professional.
Can abiraterone raise my blood pressure?
Yes. High blood pressure, low potassium and fluid retention are recognised effects of abiraterone. Blood pressure, potassium and signs of fluid retention should be monitored regularly.
What blood tests are needed while taking abiraterone?
Liver-function tests and serum potassium are important during treatment. Blood pressure and signs of fluid retention are also monitored, and people with diabetes may need closer glucose monitoring.
What should I do if I miss a dose?
If one daily dose of abiraterone or prednisone is missed, take the normal prescribed dose the following day rather than making up the missed dose. Contact your healthcare professional if more than one daily dose is missed.
Can I crush Abitate 250 mg tablets?
No. Abiraterone tablets should be swallowed whole with water and should not be crushed or chewed. Pregnant women or women who may become pregnant should also avoid handling damaged tablets without protection.
Can Cheap Generic Med ship Abitate to the United States?
Cheap Generic Med serves the United States under its international shipping model. Delivery is typically estimated at 10–14 business days after dispatch, although customs or carrier delays can extend transit. Prescription and personal-import requirements may apply.
Will my Cheap Generic Med order have tracking?
Under the standard fulfilment model, tracked international shipping is used and a tracking number should be provided after dispatch. Carrier systems may take 24–72 hours to begin showing movement.
Sources
Medical information notice: This information does not replace advice from a qualified healthcare professional. Use prescription medicine only as directed by the prescriber and the approved product information.
| Active Ingredients | Abiraterone Acetate (250Mg) |
|---|---|
| Manufacturer | RPG Life Sciences Ltd |
| Packaging | Qty |
| strength | 250mg |
| Delivery Time | 6 To 15 days |
Related products
Altraz 1 Mg (Anastrozole)
Aprecap 125 Mg+80 Mg (Palonosetron/Netupitant)
Erlonat 150 Mg (Erlotinib)
Imatib 400 Mg (Imatinib)
Mamofen 20 Mg (Tamoxifen Citrate)
Progynova 2 Mg (Estradiol)
Temoget 100 Mg (Temozolomide)
Reviews
There are no reviews yet.